Investigators compared the outcomes of patients with type 2 diabetes who continued versus stopped metformin after progressing to stage 4 chronic kidney disease.
Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
China: A recent study published in the Journal of Diabetes and its Complications highlighted dapagliflozin's (DAPA) ...
Consultant in endocrinology and diabetes Professor Vinod Patel discusses current recommended pharmacological treatment ...
Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...
A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...
Newer medications such as SGLT2 inhibitors and GLP-1 receptor agonists (GLP-1 RAs) offer significant benefits in managing diabetes, which can slow CKD progression. SGLT2 inhibitors are FDA ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...
A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback